Science Corporation plans human trials for biohybrid brain-computer interface

Apr 14, 2026

AI Summary

Science Corporation, founded by Max Hodak, is preparing to conduct its first human trials for a biohybrid brain-computer interface. Led by Dr. Murat Günel from Yale, the trials aim to implant a sensor that integrates lab-grown neurons with electronics to potentially treat neurological conditions.

Science Corporation, established in 2021 by Max Hodak, is developing a biohybrid brain-computer interface.
Dr. Murat Günel, chair of Yale Medical School’s Department of Neurosurgery, will lead the first U.S. human trials.
The company recently completed a $230 million Series C funding round, valuing it at $1.5 billion.
Its advanced product, PRIMA, aims to restore vision for individuals with blindness due to macular degeneration and is expected to be available in Europe pending regulatory approval.
The biohybrid interface will use lab-grown neurons to create a connection between electronics and the human brain, differing from traditional methods that use metal probes.
The initial human trials will test a sensor without embedded neurons, placed on top of the brain, and will not require FDA approval due to its design.
The target candidates for the trials are patients undergoing significant brain surgery, such as stroke victims.
Potential applications of the device include treating neurological conditions, monitoring brain activity, and possibly addressing diseases like Parkinson's.
The timeline for beginning trials is optimistic, with expectations set for 2027.

human trialsbrain sensorhybrid technologyneurosciencemedical robotics

Science Corporation plans human trials for biohybrid brain-computer interface

Related Stories

South Korea Considers Partnership with Hyundai for Military Robotics Amid Troop Shortage

Waymo and Wayve to Compete in Self-Driving Technology Launch in London

Exploring the Competition in Autonomous Driving Technologies

Wayve CEO Discusses Autonomous Driving and AI Licensing Strategy